SLC5A2 and chronic kidney disease: In addition, several important results from these CVOTs have led to the most recent guidelines recommending SGLT2 inhibitors as the preferred pharmacological therapy for specific patients, such as those with T2D and a high cardiovascular risk or with CVD, including HF and chronic kidney disease, regardless of their prior use of metformin [1, 2].